TY - JOUR
T1 - Systolic blood pressure and mortality in acute symptomatic pulmonary embolism
AU - Quezada, Andrés
AU - Jiménez, David
AU - Bikdeli, Behnood
AU - Moores, Lisa
AU - Porres-Aguilar, Mateo
AU - Aramberri, Mario
AU - Lima, Jorge
AU - Ballaz, Aitor
AU - Yusen, Roger D.
AU - Monreal, Manuel
AU - The RIETE Investigators
A2 - Skride, Andris
N1 - "The RIETE Investigators" saraksts, kurā iekļauts A.Skride, atrodams pielikumā pie publikācijas - Appendix B.
Link to the RIETE Registry participating centers:
https://www.riete.org/info/centros_participantes/index.php
Funding Information:
This study (PI15/00207) has been partially supported by the Instituto de Salud Carlos III (Plan Estatal de I+D+I 2013-2016) and cofinanced by the European Development Regional Fund ?A way to achieve Europe? (ERDF).We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG's support was limited to the part of RIETE outside Spain, which accounts for a 25.31% of the total patients included in the RIETE Registry. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support.
Funding Information:
Study concept and design: Quezada, Jimenez, Bikdeli, Moores, Monreal. Acquisition of data; analysis and interpretation of data; statistical analysis: Quezada, Jimenez, Bikdeli, Moores, Porres-Aguilar, Aramberri, Lima, Ballaz, Yusen, Monreal. Critical revision of the manuscript for important intellectual content: Quezada, Jimenez, Bikdeli, Moores, Porres-Aguilar, Aramberri, Lima, Ballaz, Yusen, Monreal. Study supervision: Jiménez, Monreal. The corresponding author, David Jiménez, had full access to all the data in the study and had final responsibility for the decision to submit for publication. Source of funding This study ( PI15/00207 ) has been partially supported by the Instituto de Salud Carlos III (Plan Estatal de I+D+I 2013-2016) and cofinanced by the European Development Regional Fund “A way to achieve Europe” ( ERDF ).
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background: The optimal cutoff for systolic blood pressure (SBP) level to define high-risk pulmonary embolism (PE) remains to be defined. Methods: To evaluate the relationship between SBP levels on admission and mortality in patients with acute symptomatic PE, the current study included 39,257 consecutive patients with acute symptomatic PE from the RIETE registry between 2001 and 2018. Primary outcomes included all-cause and PE-specific 30-day mortality. Secondary outcomes included major bleeding and recurrent venous thromboembolism (VTE). Results: There was a linear inverse relationship between admission SBP and 30-day all-cause and PE-related mortality that persisted after multivariable adjustment. Patients in the lower SBP strata had higher rates of all-cause death (reference: SBP 110–129 mmHg) (adjusted odds ratio [OR] 2.9; 95% confidence interval [CI], 2.0–4.2 for SBP <70 mmHg; and OR 1.7; 95% CI, 1.4–2.1 for SBP 70–89 mmHg). The findings for 30-day PE-related mortality were similar (adjusted OR 4.4; 95% CI, 2.7–7.2 for SBP <70 mmHg; and OR 2.6; 95% CI, 1.9–3.4 for SBP 70–89 mmHg). Patients in the higher strata of SBP had significantly lower rates of 30-day all-cause mortality compared with the same reference group (adjusted OR 0.7; 95% CI, 0.5–0.9 for SBP 170–190 mmHg; and OR 0.6; 95% CI, 0.4–0.9 for SBP >190 mmHg). Consistent findings were also observed for 30-day PE-related death. Conclusions: In patients with acute symptomatic PE, a low SBP portends an increased risk of all-cause and PE-related mortality. The highest mortality was observed in patients with SBP <70 mmHg.
AB - Background: The optimal cutoff for systolic blood pressure (SBP) level to define high-risk pulmonary embolism (PE) remains to be defined. Methods: To evaluate the relationship between SBP levels on admission and mortality in patients with acute symptomatic PE, the current study included 39,257 consecutive patients with acute symptomatic PE from the RIETE registry between 2001 and 2018. Primary outcomes included all-cause and PE-specific 30-day mortality. Secondary outcomes included major bleeding and recurrent venous thromboembolism (VTE). Results: There was a linear inverse relationship between admission SBP and 30-day all-cause and PE-related mortality that persisted after multivariable adjustment. Patients in the lower SBP strata had higher rates of all-cause death (reference: SBP 110–129 mmHg) (adjusted odds ratio [OR] 2.9; 95% confidence interval [CI], 2.0–4.2 for SBP <70 mmHg; and OR 1.7; 95% CI, 1.4–2.1 for SBP 70–89 mmHg). The findings for 30-day PE-related mortality were similar (adjusted OR 4.4; 95% CI, 2.7–7.2 for SBP <70 mmHg; and OR 2.6; 95% CI, 1.9–3.4 for SBP 70–89 mmHg). Patients in the higher strata of SBP had significantly lower rates of 30-day all-cause mortality compared with the same reference group (adjusted OR 0.7; 95% CI, 0.5–0.9 for SBP 170–190 mmHg; and OR 0.6; 95% CI, 0.4–0.9 for SBP >190 mmHg). Consistent findings were also observed for 30-day PE-related death. Conclusions: In patients with acute symptomatic PE, a low SBP portends an increased risk of all-cause and PE-related mortality. The highest mortality was observed in patients with SBP <70 mmHg.
KW - Mortality
KW - Pulmonary embolism
KW - Systolic blood pressure
UR - http://www.scopus.com/inward/record.url?scp=85076234832&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2019.11.102
DO - 10.1016/j.ijcard.2019.11.102
M3 - Article
C2 - 31761399
AN - SCOPUS:85076234832
SN - 0167-5273
VL - 302
SP - 157
EP - 163
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -